周一夜盘，脑再生科技（RGC）股价再度下挫，大跌5.06%，延续了近日的暴跌趋势。这家专注于开发中药治疗注意力缺陷多动障碍（ADHD）和自闭症谱系障碍（ASD）的生物科技公司，近期股价走势剧烈波动，引发市场广泛关注。
据悉，脑再生科技股价在上周经历了戏剧性的涨跌。该股此前两个交易日内累计上涨近400%，最高触及83.6美元的历史新高。然而，好景不长，上周五股价突然暴跌40%，周一又继续大跌超30%，报26.42美元。分析人士指出，如此剧烈的股价波动反映了投资者情绪的快速转变。
对于脑再生科技股价的持续下跌，市场普遍认为这是前期快速上涨后的正常回调。部分投资者选择获利了结，导致股价承压。此外，考虑到公司作为早期生物科技企业的特性，一些投资者可能对其估值产生疑虑，进而引发抛售。目前，市场将密切关注该公司的基本面发展和后续公告，以评估其长期投资价值。投资者也需警惕高风险，理性看待该股的投资前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.